XML 69 R47.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Collaborative, Licensing and Other Arrangements - Novartis - Additional Information (Details) |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Dec. 31, 2015 USD ($) | Jan. 31, 2014 USD ($) | Nov. 30, 2008 USD ($) Product | Dec. 31, 2015 USD ($) | Dec. 31, 2015 USD ($) | Dec. 31, 2014 USD ($) | Dec. 31, 2013 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
License and collaborative fees |  |  |  |  | $ 49,064,000 | $ 5,683,000 | $ 11,028,000
Novartis [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upfront payment received |  |  |  | $ 37,000,000 |  |  |
Performance deliverable period for license and regulatory services |  |  |  |  | 90 days |  |
Performance deliverable period for transfer of materials, process and knowhow |  |  |  |  | 90 days |  |
Performance deliverables value on stand alone basis |  |  |  |  | $ 0 |  |
Novartis [Member] | Development Milestone [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Future milestone payments, maximum |  |  | $ 14,000,000 |  |  |  |
Collaborative Arrangement [Member] | Novartis [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Proceeds from collaborators |  |  | 6,200,000 |  |  |  |
Reduction in debt under restructured agreement |  |  | $ 7,500,000 |  |  |  |
Royalty right expiration period |  |  | 20 years |  |  |  |
Milestone received under the collaboration agreement | $ 0 |  |  |  |  |  | $ 7,000,000
Repayment of debt |  | $ 1,750,000 |  |  |  |  |
Percentage of milestone received |  | 25.00% |  |  |  |  |
License and collaborative fees |  |  |  |  | 0 | $ 0 |
Maximum borrowing capacity under loan agreement | $ 50,000,000 |  |  | $ 50,000,000 | $ 50,000,000 |  |
Research and development expenses funded through loan facility, maximum (in hundredths) |  |  |  |  | 75.00% |  |
Upfront payment received |  |  |  |  | $ 37,000,000 |  |
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones |  |  |  |  | $ 480,000,000 |  |
Collaborative Arrangement [Member] | Novartis [Member] | Development Milestone [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Number of ongoing product programs with potential royalty right milestone payments | Product |  |  | 2 |  |  |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Decrease for amounts of indebtedness forgiven by the holder of the debt instrument. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(f)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_DebtInstrumentDecreaseForgiveness
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(d),(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseAndServicesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations. + References No definition available. + Details
Name: | us-gaap_RepaymentsOfDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Refers to the maximum future development and sales milestone payments to be received by the Company. + References No definition available. + Details
Name: | xoma_CollaborativeArrangementContingentConsiderationPotentialCashPaymentMaximum
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum percentage of aggregate costs of clinical research and development expenses that are funded through a debt instrument under collaborative arrangements and are not incurred by the Company. + References No definition available. + Details
Name: | xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum borrowing capacity for a debt instrument under the loan agreement. + References No definition available. + Details
Name: | xoma_DebtInstrumentMaximumBorrowingCapacity
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Eligible milestone payments receivable upon achievement of development regulatory and commercial milestones. + References No definition available. + Details
Name: | xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Refers to the payment percentage of milestone received under the collaboration agreement. + References No definition available. + Details
Name: | xoma_MilestoneReceivedUnderCollaborationAgreement
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of ongoing product programs with potential royalty right milestone payments. + References No definition available. + Details
Name: | xoma_NumberOfOngoingProductProgramsWithPotentialRoyaltyRightMilestonePayments
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Refers to percentage of milestone received. + References No definition available. + Details
Name: | xoma_PercentageOfMilestoneReceived
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Performance deliverable period for license and regulatory services + References No definition available. + Details
Name: | xoma_PerformanceDeliverablePeriodForLicenseAndRegulatoryServices
Namespace Prefix: | xoma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Performance deliverable period for transfer of materials, process and knowhow + References No definition available. + Details
Name: | xoma_PerformanceDeliverablePeriodForTransferOfMaterialsProcessAndKnowhow
Namespace Prefix: | xoma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Performance deliverables value on stand alone basis + References No definition available. + Details
Name: | xoma_PerformanceDeliverablesValueOnStandAloneBasis
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Proceeds from upfront payment. + References No definition available. + Details
Name: | xoma_ProceedsFromUpfrontPayment
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Refers to royalty right expiration period. + References No definition available. + Details
Name: | xoma_RoyaltyRightExpirationPeriod
Namespace Prefix: | xoma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xoma_NovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xoma_DevelopmentMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |